ENHERTU Granted Two Breakthrough Therapy Designations In U.S. For Patients Across Multiple HER2 Expressing Cancers
Portfolio Pulse from Happy Mohamed
ENHERTU, a drug developed by Daiichi Sankyo and AstraZeneca, has been granted two additional Breakthrough Therapy Designations (BTDs) in the U.S. for the treatment of adult patients with certain types of HER2 positive tumors. The drug has now received a total of seven BTDs. The FDA grants BTDs to accelerate the development and review of potential new medicines that address a significant unmet medical need.
August 31, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's jointly developed drug ENHERTU has received two additional Breakthrough Therapy Designations in the U.S. This could potentially accelerate the drug's development and review process.
The granting of additional Breakthrough Therapy Designations for ENHERTU could potentially accelerate the drug's development and review process, which could lead to earlier approval and commercialization. This could have a positive impact on AstraZeneca's future revenues and profitability, thus potentially boosting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100